Daclatasvir Tablets are an antiviral medicine used in the treatment of chronic Hepatitis C virus (HCV) infection. They belong to a class of medicines called direct-acting antivirals (DAAs).

Here are the key details:

• Composition: Each tablet typically contains Daclatasvir dihydrochloride as the active ingredient, in strengths such as 30 mg or 60 mg.

• Mode of Action: Daclatasvir works by inhibiting the NS5A protein of the hepatitis C virus, which is essential for viral replication and assembly. By blocking this protein, it helps reduce the amount of virus in the body.

• Use: It is not used alone but in combination with other antiviral agents such as Sofosbuvir, with or without Ribavirin, depending on the type of HCV genotype being treated.

• Dosage Form: Supplied as film-coated oral tablets.

• Treatment Goal: The aim is to achieve a sustained virologic response (SVR), meaning the virus becomes undetectable in the blood after treatment is completed, often referred to as a “cure.”

• Duration of Therapy: Usually ranges between 12 to 24 weeks, depending on the HCV genotype, presence of cirrhosis, and prior treatment history.

• Side Effects: Commonly reported ones include headache, fatigue, nausea, and anemia (especially when combined with Ribavirin).

• Precautions:

  • Should not be used alone; always in combination with other HCV medicines.

  • Caution in patients with severe liver problems.

  • Possible interactions with other drugs, so a review of current medications is necessary before starting treatment.